CDLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardlytics Inc (CDLX) is not a strong buy for a beginner investor with a long-term focus at this moment. Despite the recent price surge, the company's financials show significant declines in revenue, net income, and EPS, coupled with a lack of positive news or strong analyst sentiment. The technical indicators and options data do not provide a compelling case for immediate entry, and the lack of Intellectia Proprietary Trading Signals further supports a cautious approach.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 71.814, which is near overbought territory but still neutral. Moving averages are converging, suggesting indecision in the trend. The stock closed above the first resistance level (R1: 1.134), showing short-term strength, but the overall trend lacks strong confirmation.
Hedge funds have significantly increased their buying activity, up 361.26% over the last quarter. The stock showed a 13% regular market gain, indicating short-term bullish momentum.
Analyst ratings have been downgraded, with price targets reduced to $1 and $1.25, reflecting low confidence in the stock's near-term performance. The company's Q1 guidance and financials highlight challenges, including the impact of the BofA exit and Bridg divestiture. No recent news or congress trading data to support a positive outlook.
In Q4 2025, revenue dropped by -24.19% YoY to $56.1M. Net income fell by -47.08% YoY to -$8.25M, and EPS declined by -51.61% YoY to -$0.15. Gross margin also decreased to 45.45%, down -3.28% YoY, indicating deteriorating financial health.
Recent analyst ratings are negative. Evercore ISI lowered the price target to $1 from $2, maintaining an In Line rating. Lake Street reduced the price target to $1.25 from $1.50, keeping a Hold rating. Analysts view the stock as being in 'show me' territory, with concerns over near-term challenges.
